Sector: Pharmaceuticals Biotechnology and Life Sciences

The SPDR Health Care Select Sector exchange-traded fund is less than a sneeze from its recent highs, and some bulls are looking for it to pop.   Read More

Few stock sectors are as reliable as drugs and health care, and astute investors know that companies such as Merck, Pfizer, and Abbott Laboratories have delivered healthy returns over the years. One stock that investors have become less enamored with, however, is Johnson & Johnson.    Read More

The makers of a deer antler velvet product are suing Major League Baseball for libel after the league told players to stop taking the performance enhancer so as not to risk testing positive for a steroid that wasn't listed as an ingredient.   Read More

AstraZeneca may be lacking both drugs and a CEO, but for brave investors this might be the time to buy the stock.    Read More

Gregory T. Lucier, CEO of Life Technologies, gives Cramer the lowdown.   Read More

Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.    Read More

A two-person surgical team has created a new, inexpensive bone-grafting device without having to go to big pharma.   Read More

Investors can expect a muted first-quarter earnings season, and should add pharmaceutical stocks to their portfolios to guard against potentially rocky times ahead, according to investment bank UBS.   Read More

Why Amylin Pharmaceuticals shareholders should demand transparency and a public explanation of recent takeover talk.    Read More

The Spectrum Pharmaceuticals growth party is over.    Read More